Biotechnology
Filter News
Found 21,804 articles
-
Pressure BioSciences Initiates Aggressive Marketing and Sales Strategy Expected to Drive Significant Expansion Into China
11/1/2017
Pressure BioSciences announced that Professor Tiannan Guo's laboratory at Westlake Institute for Advanced Study ("WIAS") has been named the Company's first Center of Excellence ("CoE") in China.
-
Atara Announces Two Presentations at 59th American Society of Hematology Annual Meeting, Including Positive Interim Results From a Multicenter Expanded Access Study of ATA129 for Patients with Epstein-Barr Virus-Associated Cancers
11/1/2017
The Company’s collaborating investigators at Memorial Sloan Kettering Cancer Center will present, on behalf of eight major transplant centers in the U.S.
-
Charles River Laboratories Presents Newly Expanded Capabilities at Neuroscience 2017
11/1/2017
The meeting, which brings together over 30,000 researchers from more than 80 countries, is taking place from November 11-15 in Washington, DC.
-
ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in Celiac Disease
11/1/2017
They first demonstrated the safety and tolerability and immunological and intestinal effects of Nexvax2 following initial step-wise escalating doses and maintenance doses higher than the previously determined maximum tolerated dose (MTD) for fixed dose schedules.
-
The companies will advance the new Relaxin development candidate, AZD7970, toward the clinic as an investigational treatment for heart failure.
-
GB Sciences Inducts Scientific Advisory Board: Dr. Andrea Small-Howard of GB Sciences, Dr. Helen Turner of Chaminade University, Dr. Norbert Kaminsky of Michigan State University, and Dr. Carlos Ríos-Bedoya of McLaren Health
11/1/2017
GB Sciences inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences' intellectual property portfolio.
-
Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations
11/1/2017
Net product revenue in the third quarter of 2017 achieved record levels.
-
Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results
11/1/2017
The company will host a conference call to provide a corporate update.
-
Here's a closer look at six drugs facing FDA decisions in November.
-
Amgen and Kirin have decided to dissolve their joint venture, Kirin-Amgen.
-
3 Biotechs Bloodied Celgene Could Take Out
10/31/2017
Investors and analysts are wondering if the company should buy a biotech to bolster its pipeline and bottom line. -
Shares of Voyager have fallen more than 12 percent in premarket trading after Sanofi Genzyme walked away from its $845M gene therapy treatment for Parkinson’s disease.
-
Astra and Incyte are pushing forward on the development of immunotherapy combination treatments.
-
X-Spine is shutting down its Ohio facility and terminating the employees between December and February 2018.
-
Stemline Therapeutics Announces that Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Ce...
10/31/2017
Based on feedback from the FDA, Stemline remains on track to begin submission of its BLA in the 4Q17-1Q18 timeframe. -
The money is intended to to fuel European biotech startups.
-
Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company
10/31/2017
Mr. Wechsler is a seasoned pharma executive with more than 25 years of healthcare experience.
-
Mr. Eisenberg joined the Xenetic management team in December 2016 as its COO.
-
PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
10/31/2017
PDL BioPharma today issued the following statement in response to the Neos Board of Directors' rejection of PDL's October 26 proposal to acquire Neos for $10.25 per share in cash.
-
NeoMatrix Therapeutics Enters Clinical Stage As Investigational New Drug Application for NMT-cP12 Goes Into Effect
10/31/2017
With this active IND, NeoMatrix becomes a clinical-stage company and will study NMT-cP12, a small peptide-drug candidate,